Login Register Cart 0
Generic placeholder image

Current Psychiatry Research and Reviews

Editor-in-Chief

ISSN (Print): 2666-0822
ISSN (Online): 2666-0830

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Review Article

Factors Influencing Quetiapine Pharmacokinetic Variability: A Review of Population Pharmacokinetics

Author(s): Janthima Methaneethorn*

Volume 20, Issue 2, 2024

Published on: 16 February, 2023

Page: [94 - 105] Pages: 12

DOI: 10.2174/2666082219666230111145821

Price: $65

Abstract

Atypical antipsychotic quetiapine (QTP) exhibits high pharmacokinetic variability and population pharmacokinetic (PopPK) analysis is one of the approaches used to characterize factors influencing QTP pharmacokinetic variability. Though QTP is not regarded as a narrow therapeutic index drug, knowledge of this area is of importance. Thus, this review was conducted to summarize significant predictors for QTP pharmacokinetic variability identified using a PopPK analysis and to explore any knowledge gaps to be investigated. PubMed, Scopus, and CINAHL Complete databases were searched for eligible studies, and 75 articles were identified. Of these, only five studies were included as they were conducted using a nonlinear mixed-effects approach. This review found that only limited predictors for QTP pharmacokinetics were identified, with body weight being a predictor for the volume of distribution and age and γ-glutamyl transpeptidase being predictors for QTP clearance. None of the studies included elderly patients aged >65 years, and thus factors associated with aging were not investigated. Also, most of the participants in the PopPK analyses were from clinical trials which might not reflect real-world patients e.g., the impacts of polypharmacy may not be available. Moreover, while a population pharmacokinetic-pharmacodynamic model explaining QTP exposure and clinical response using the scores of the Brief Psychiatric Rating Scale is available, knowledge relevant to the relationship between exposure and QTP side effects has not been explored. Based on this limited information, future PopPK research encompassing a wide range of patient characteristics is required.

« Previous Next »
Graphical Abstract

[1]
SEROQUEL package insert. Wilmington (DE): Astrazeneca pharmaceuticals 2013.
[2]
SEROQUEL XR package insert. Wilmington (DE): Astrazeneca pharmaceuticals 2018.
[3]
Kusumi I, Boku S, Takahashi Y. Psychopharmacology of atypical antipsychotic drugs: From the receptor binding profile to neuroprotection and neurogenesis. Psychiatry Clin Neurosci 2015; 69(5): 243-58.
[http://dx.doi.org/10.1111/pcn.12242] [PMID: 25296946]
[4]
Markowitz JS, Brown CS, Moore TR. Atypical antipsychotics. Part I: Pharmacology, pharmacokinetics, and efficacy. Ann Pharmacother 1999; 33(1): 73-85.
[http://dx.doi.org/10.1345/aph.17215] [PMID: 9972387]
[5]
DeVane CL, Nemeroff CB. Clinical pharmacokinetics of quetiapine: An atypical antipsychotic. Clin Pharmacokinet 2001; 40(7): 509-22.
[http://dx.doi.org/10.2165/00003088-200140070-00003] [PMID: 11510628]
[6]
Bui K, Earley W, Nyberg S. Pharmacokinetic profile of the extended-release formulation of quetiapine fumarate (quetiapine XR): Clinical implications. Curr Med Res Opin 2013; 29(7): 813-25.
[http://dx.doi.org/10.1185/03007995.2013.794774] [PMID: 23574265]
[7]
Estevez-Carrizo FE, Parrillo S, Ercoli MC, Estevez-Parrillo FT. Single-dose relative bioavailability of a new quetiapine fumarate extended-release formulation: A postprandial, randomized, open-label, two-period crossover study in healthy Uruguayan volunteers. Clin Ther 2011; 33(6): 738-45.
[http://dx.doi.org/10.1016/j.clinthera.2011.05.002] [PMID: 21704238]
[8]
Boulton DW, DeVane CL, Liston HL, Markowitz JS. In vitro P-glycoprotein affinity for atypical and conventional antipsychotics. Life Sci 2002; 71(2): 163-9.
[http://dx.doi.org/10.1016/S0024-3205(02)01680-6] [PMID: 12031686]
[9]
Gefvert O. Bergström M, Långström B, Lundberg T, Lindström L, Yates R. Time course of central nervous dopamine-D 2 and 5-HT 2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel®) in patients with schizophrenia. Psychopharmacology (Berl) 1998; 135(2): 119-26.
[http://dx.doi.org/10.1007/s002130050492] [PMID: 9497016]
[10]
Hiemke C, Bergemann N, Clement HW, Conca A, Deckert J, Domschke K, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: Update 2017. Pharmacopsychiatry 2018; 51(1-02): 9-62.
[11]
Fidler M, Wilkins JJ, Hooijmaijers R, et al. Nonlinear mixed-effects model development and simulation using nlmixr and related R open-source packages. CPT Pharmacometrics Syst Pharmacol 2019; 8(9): 621-33.
[http://dx.doi.org/10.1002/psp4.12445] [PMID: 31207186]
[12]
Methaneethorn J, Leelakanok N. Pharmacokinetic variability of phenobarbital: A systematic review of population pharmacokinetic analysis. Eur J Clin Pharmacol 2021; 77(3): 291-309.
[http://dx.doi.org/10.1007/s00228-020-03011-x] [PMID: 33078242]
[13]
Methaneethorn J, Leelakanok N. Sources of lamotrigine pharmacokinetic variability: A systematic review of population pharmacokinetic analyses. Seizure 2020; 82: 133-47.
[http://dx.doi.org/10.1016/j.seizure.2020.07.014] [PMID: 33060011]
[14]
Kamp J, Olofsen E, Henthorn TK, van Velzen M, Niesters M, Dahan A. Ketamine pharmacokinetics. Anesthesiology 2020; 133(6): 1192-213.
[http://dx.doi.org/10.1097/ALN.0000000000003577] [PMID: 32997732]
[15]
Fukushi R, Nomura Y, Katashima M, Komatsu K, Sato Y, Takada A. Population pharmacokinetics analysis of quetiapine extended-release formulation in Japanese patients with bipolar depression. Clin Ther 2020; 42(6): 1067-1076.e2.
[http://dx.doi.org/10.1016/j.clinthera.2020.04.006] [PMID: 32518042]
[16]
Shilbayeh SAR, Sy SKB, Melhem M, Zmeili R, Derendorf H. Quantitation of the impact of CYP3A5 A6986G polymorphism on quetiapine pharmacokinetics by simulation of target attainment. Clin Pharmacol Drug Dev 2015; 4(5): 387-94.
[http://dx.doi.org/10.1002/cpdd.172] [PMID: 27137148]
[17]
Kimko H, Reele SSB, Holford NHG, Peck CC. Prediction of the outcome of a phase 3 clinical trial of an antischizophrenic agent (quetiapine fumarate) by simulation with a population pharmacokinetic and pharmacodynamic model. Clin Pharmacol Ther 2000; 68(5): 568-77.
[http://dx.doi.org/10.1067/mcp.2000.110975] [PMID: 11103759]
[18]
Zhou D, Bui KH, Li J, Al-Huniti N. Population pharmacokinetic modeling of quetiapine after administration of seroquel and seroquel XR formulations to Western and Chinese patients with schizophrenia, schizoaffective disorder, or bipolar disorder. J Clin Pharmacol 2015; 55(11): 1248-55.
[http://dx.doi.org/10.1002/jcph.544] [PMID: 25975812]
[19]
Korell J, Green B, Rae A, Remmerie B, Vermeulen A. Determination of plasma concentration reference ranges for oral aripiprazole, olanzapine, and quetiapine. Eur J Clin Pharmacol 2018; 74(5): 593-9.
[http://dx.doi.org/10.1007/s00228-018-2419-3] [PMID: 29392351]
[20]
Bakken GV, Rudberg I, Molden E, Refsum H, Hermann M. Pharmacokinetic variability of quetiapine and the active metabolite N-desalkylquetiapine in psychiatric patients. Ther Drug Monit 2011; 33(2): 222-6.
[http://dx.doi.org/10.1097/FTD.0b013e31821160c4] [PMID: 21383647]
[21]
Mould DR, Upton RN. Basic concepts in population modeling, simulation, and model-based drug development-part 2: Introduction to pharmacokinetic modeling methods. CPT Pharmacometrics Syst Pharmacol 2013; 2(4): e38.
[22]
Bender AD. Effect of age on intestinal absorption: Implications for drug absorption in the elderly. J Am Geriatr Soc 1968; 16(12): 1331-9.
[http://dx.doi.org/10.1111/j.1532-5415.1968.tb02776.x] [PMID: 5698660]
[23]
Hamed R, AlJanabi R, Sunoqrot S, Abbas A. The effect of pH, buffer capacity and ionic strength on quetiapine fumarate release from matrix tablets prepared using two different polymeric blends. Drug Dev Ind Pharm 2017; 43(8): 1330-42.
[http://dx.doi.org/10.1080/03639045.2017.1318897] [PMID: 28402145]
[24]
Weiss J, Dormann SMG, Martin-Facklam M, Kerpen CJ, Ketabi-Kiyanvash N, Haefeli WE. Inhibition of P-glycoprotein by newer antidepressants. J Pharmacol Exp Ther 2003; 305(1): 197-204.
[http://dx.doi.org/10.1124/jpet.102.046532] [PMID: 12649369]
[25]
Elmeliegy M, Vourvahis M, Guo C, Wang DD. Effect of P-glycoprotein (P-gp) inducers on exposure of P-gp substrates: Review of clinical drug–drug interaction studies. Clin Pharmacokinet 2020; 59(6): 699-714.
[http://dx.doi.org/10.1007/s40262-020-00867-1] [PMID: 32052379]
[26]
Kinirons MT, O’Mahony MS. Drug metabolism and ageing. Br J Clin Pharmacol 2004; 57(5): 540-4.
[http://dx.doi.org/10.1111/j.1365-2125.2004.02096.x] [PMID: 15089805]
[27]
Bakken GV, Rudberg I, Christensen H, Molden E, Refsum H, Hermann M. Metabolism of quetiapine by CYP3A4 and CYP3A5 in presence or absence of cytochrome B5. Drug Metab Dispos 2009; 37(2): 254-8.
[http://dx.doi.org/10.1124/dmd.108.023291] [PMID: 19022943]
[28]
Kim KA, Joo HJ, Lee HM, Park JY. Influence of ABCB1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of quetiapine in healthy volunteers. Pharmacogenet Genomics 2014; 24(1): 35-42.
[http://dx.doi.org/10.1097/FPC.0000000000000020] [PMID: 24240480]
[29]
Kunutsor SK. Gamma-glutamyltransferase-friend or foe within? Liver Int 2016; 36(12): 1723-34.
[http://dx.doi.org/10.1111/liv.13221] [PMID: 27512925]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy